ストックスクリーナーアプリを入手
1.88
4.57%
-0.09
アフターアワーズ：
1.88
前日終値:
$1.97
開ける：
$1.8
24時間の取引高:
83,367
Relative Volume:
2.39
時価総額：
$44.31M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.00%
1か月 パフォーマンス:
-4.08%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.69
$1.93
1週間の範囲:
$1.69
$2.02
52週間の値動き範囲:
$1.35
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
RNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.88 | 44.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2017-07-24 | 開始されました | BofA/Merrill | Buy |
| 2017-07-24 | 開始されました | Jefferies | Buy |
| 2017-07-24 | 開始されました | William Blair | Outperform |
Rein Therapeutics Inc (RNTX) 最新ニュース
Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
Rein Therapeutics Paused Its Phase 2 Renew Trial Of Lti-03 In The U.S. - marketscreener.com
Rein Therapeutics Pauses U.S. Enrollment for RENEW Trial - TipRanks
Rein Therapeutics pauses dosing in lung disease trial after US FDA places hold - TradingView
New National Poll Finds Overwhelming Majorities of Voters Want "America First" Reforms of Big Pharma’s Business Practices, Want to Limit Direct-to-Consumer Pharmaceutical Advertising, & Support President Trump’s Executive Order on Drug Pricing - Yahoo Finance
KC GLOBAL MEDIA AND REIN ENTERTAINMENT JOIN FORCES FOR A RIVETING REALITY-DRIVEN DRUG WAR SERIES - Yahoo Finance
In Spain, short-term rentals surge despite bid to rein in overtourism - Yahoo
President Trump Should Rein in Biden Era Actions Targeting U.S. Businesses - Yahoo
Rein Therapeutics doses first subject in Phase II trial to treat IPF - Yahoo Finance
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com
IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf - marketscreener.com
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV S - GuruFocus
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV Stock News - GuruFocus
Breakthrough IPF Drug Enters Phase 2 Trial: Rein's Novel Treatment Could Transform Pulmonary Fibrosis Care - Stock Titan
Knee Pain Relief Through The Ear? New Study Says It's Possible - WFMZ.com
U.S. Had 1.5 Million Excess Deaths Following Pandemic - WFMZ.com
Exercise Improves Odds Against Cancer - WFMZ.com
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Recruitment underway for Phase 2 trial of IPF inhalation therapy - Pulmonary Fibrosis News
Prices for new US drugs doubled in 4 years as focus on rare disease grows - Reuters
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference - Nasdaq
Rein Therapeutics Reports Q1 2025 Financial Results - TipRanks
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GuruFocus
Rein Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment - Yahoo Finance
Rein Therapeutics Announces Initiation Of Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com
Rein Therapeutics (RNTX) Begins Phase 2 Trial for IPF Treatment | RNTX Stock News - GuruFocus
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Rein Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment - Yahoo Finance
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - Citizen Tribune
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference - The Victoria Advocate
Breakthrough Lung Regeneration Study: Rein Therapeutics to Present New IPF Treatment Data at ATS 2025 - Stock Titan
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases - The Malaysian Reserve
Rein Therapeutics (RNTX) Secures Two Key Patents for Innovative Lung Treatment | RNTX Stock News - GuruFocus
Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases - marketscreener.com
Antibiotics Might Increase Risk of Childhood Asthma, Allergies - WFMZ.com
Muscle Quality Could Be Key To Successful Hip Replacement - WFMZ.com
Early Menopause Might Mean Greater Age-Related Brain Decline - WFMZ.com
Microplastics Could Be Contributing To Clogged Arteries - WFMZ.com
Psilocybin Use Dramatically Increasing In U.S. - WFMZ.com
Tesla Board Gets an Earful From State Treasurers Over Musk’s Focus - Yahoo Finance
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial - Frontiers
Rein Therapeutics Announces a Publication in Biomedicines on the - GuruFocus
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - MarketScreener
Cancer-fighting implant shows promise in treating tumors - WFMZ.com
Rein Therapeutics Inc (RNTX) 財務データ
Rein Therapeutics Inc (RNTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):